Insulin Resistance as the Underlying Cause for the Metabolic Syndrome

Medical Clinics of North America

Volumn 91, Issue 6, 2007, Pages 1063-1077

  Lann, Danielle ^a   LeRoith, Derek ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B48; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; C REACTIVE PROTEIN; CYTOKINE; ENDOTHELIN 1; GLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 1BETA; LIPID; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; RAMIPRIL; STRESS ACTIVATED PROTEIN KINASE 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

CYTOKINE RELEASE; DISEASE EXACERBATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HORMONAL REGULATION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

BLOOD GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; METABOLIC SYNDROME X; PROGNOSIS; RISK FACTORS;

EID: 35448932394     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2007.06.012     Document Type: Review

References (86)

1. Smith D.O., and LeRoith D. Insulin resistance, pre-diabetes, and the prevention of type 2 diabetes. Clin Cornerstone 6 2 (2004) 7-6
2. Setsi G. Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol Metab 20 4 (2006) 665-679
3. LeRoith D. Beta cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 113 6A (2002) 3s-11s
4. Vauhkonen I., Niskanen L., Vanninen E., et al. Defects in insulin secretion and insulin action in non-insulin dependent diabetes mellitus are inherited: metabolic studies on offspring of diabetic probands. J Clin Invest 101 (1998) 86-96
5. Kashyap S., Belfort R., Gastaldelli A., et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to type 2 diabetes. Diabetes 52 (2003) 2461-2474
6. Del Prato S., Leonetti F., Simonson D.C., et al. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 37 (1994) 1025-1035
7. Roth J., Qiang X., Marban S.L., et al. The obesity pandemic: where have we been and where are we going?. Obes Res 12 Suppl 2 (2004) 88s-101s
8. Marban S.L., and Roth J. Transgenic hyperinsulinemia: a mouse model of insulin resistance and glucose intolerance without obesity. In: Shafrir E. (Ed). Lessons from animal diabetes IV. 6th edition (1996), Birkhauser, Boston 201-224
9. Biddinger S.B., and Kahn C.R. From mice to men: insights into insulin resistance syndromes. Annu Rev Physiol 68 (2006) 123-158
10. George S., Rochford J.J., Wolfrum C., et al. A family with severe insulin resistance and diabetes due to a mutation in Akt2. Science 304 5675 (2004) 1325-1328
11. Roth R.A., Liui F., Chin J.E., et al. Biochemical mechanisms of insulin resistance. Horm Res 41 Suppl 2 (1994) 51-55
12. Paz K., Hemi R., LeRoith D., et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Bio Chem 272 47 (1997) 29911-29918
13. Kido Y., Burks D.J., Withers D., et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 105 2 (2000) 199-205
14. Bouche C., Serdy S., Kahn C.R., et al. The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev 25 5 (2004) 807-830
15. Watson R.T., and Pessin J.E. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res 56 (2001) 175-193
16. Saltiel A.R., and Pessin J.E. Insulin signaling pathways in time and space. Trends Cell Biol 12 2 (2002) 65-71
17. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate: evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin dependent diabetes mellitus. J Clin Invest 89 (1992) 1069-1075
18. Cline C.W., Petersen K.F., Krssak M., et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341 (1999) 240-246
19. Zisman A., Peroni O.D., Abel E.D., et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med 6 (2000) 924-928
20. Petersen K.F., Krssak M., Inzucchi S., et al. Mechanism of troglitazone action in type 2 diabetes. Diabetes 49 (2000) 827-831
21. Shintani M., Nishimura H., Yonemitsu S., et al. Troglitazone not only increases GLUT4 but also increases its translocation in rat adipocytes. Diabetes 50 (2001) 2296-3000
22. Al-Kahlili L., Forsgren M., Kannisto K., et al. Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1. Diabetologia 48 6 (2005) 1173-1179
23. Yang J., and Holman G.D. Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis. Endocrinology 147 6 (2006) 2728-2736
24. Goodyear L.J., and Kahn B.B. Exercise glucose transport, and insulin sensitivity. Annu Rev Med 49 (1998) 235-261
25. Kim H.J., Lee J.S., and Kim C.K. Effect of exercise training on muscle glucose transporter 4 protein and intramuscular lipid content in elderly men with impaired glucose tolerance. Eur J Appl Physiol 93 3 (2004) 353-358
26. Cherrington A.D. Banting lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 53 (1999) 1633-1642
27. Taniguchi C.M., Kondo T., Sajan M., et al. Divergent regulation of hepatic glucose and lipid metabolism by phophoinositide 3-kinse via Akt and PKCλ/ζ. Cell Metab 3 (2006) 343-353
28. Puigserver P., Rhee J., Donovan J., et al. Insulin-regulated hepatic gluconeogenesis through FoxO1-PCG-1alpha interaction. Nature 423 (2003) 550-555
29. Accili D., and Arden K.C. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117 4 (2004) 421-426
30. Randle P.J., Garland P.B., Hales C.N., et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 (1963) 785-789
31. Shulman G.I. Cellular mechanisms of insulin resistance. J Clin Invest 106 (2000) 171-176
32. Sarafidis P.A., and Bakris G.L. Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance?. J Hum Hypertens 21 (2007) 12-19
33. Reaven G.M., Hollenbeck C., Jeng C.Y., et al. Measurement of plasma glucose, free fatty acid, lactate and insulin for 24h in patients with NIDDM. Diabetes 37 (1988) 1020-1024
34. Boden G., Jadali F., White J., et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 88 (1991) 960-966
35. Santomauro A.T., Boden G., Silva M.E., et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and non-diabetic subjects. Diabetes 48 (1999) 1836-1841
36. Belfort R., Mandarino L., Kashyap S., et al. Dose-response effect of elevated plasma free fatty acid on Insulin signaling. Diabetes 54 (2005) 1640-1648
37. Schwartz J.M., Linfoot P., Dare D., et al. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 77 (2003) 43-50
38. Iozzo P., Turpeinen A.K., Takala T., et al. Defective liver disposal of free fatty acids in patients with impaired glucose tolerance. J Clin Endocrinol Metab 89 (2004) 3496-3502
39. Merkel M., Eckel R.H., Goldberg I.J., et al. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 43 (2002) 1997-2006
40. Altomonte J., Cong L., Harbaran S., et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 114 (2004) 1493-1503
41. Bjorkegren J., Packard C.J., Hamsten A., et al. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res 37 (1996) 76-86
42. Chahil T., and Ginsberg H.N. Diabetic dyslipidemia. Endocrinol Metab Clin North Am 35 3 (2006) 491-510
43. Zheng X.L., Matsubara S., Diao C., et al. Activation of apoprotein AI gene expression by protein kinase A and C through transcription factor, Sp1. J Biol Chem 275 (2000) 31747-31754
44. Horowitz B.S., Goldberg I.J., Merab J., et al. Increased plasma and renal clearance of exchangeable pool of apolipoproteinA-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 91 (1993) 1743-1760
45. Vajo Z., Terry J.G., and Brinton E.A. Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in post-menopausal women. Atherosclerosis 152 (2002) 229-237
46. Mooradian A.D., Haas M.J., and Wong N.C. Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes 53 (2004) 513-520
47. Haas M.J., Horani M.H., Wong N.C., et al. Induction of the apolipoprotein AI promoter by Sp1 is repressed by saturated fatty acids. Metabolism 53 10 (2004) 1342-1348
48. Haas M.J., Horani M., Mreyoud A., et al. Suppression of apoprotein A-I gene expression in HepG2 cells by TNF-α and IL-1β. Biochim Biophys Acta 1623 (2003) 120-128
49. Rubins H.B., Robins S.J., Collins D., et al. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
50. Vega G.L., Cater N.B., Meguro S., et al. Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 95 11 (2005) 1309-1313
51. Al Majali K., Cooper M.B., Staels B., et al. The effect of sensitization to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 49 3 (2006) 527-537
52. Greco A.V., Mingrone G., Giancaterini A., et al. Insulin resistance in morbid obesity: reversal with intramyocellular depletion. Diabetes 51 (2002) 144-151
53. De Luca C., and Olefsky J.M. Stressed out about obesity and insulin resistance. Nat Med 12 (2006) 41-42
54. Trayhurn P., and Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92 (2004) 347-355
55. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
56. Hundal R.S., Petersen K.F., Mayerson A.B., et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109 (2002) 1321-1326
57. Qi Y., Nie Z., Lee Y.S., et al. Loss of resistin glucose homeostasis in leptin deficiency. Diabetes 55 11 (2006) 3083-3090
58. Weisberg S.P., McCann D., Desai M., et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112 12 (2003) 1796-1808
59. Salmenniemi U., Ruotsalainen E., Pihlajamaki J., et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 110 (2004) 3842-3848
60. Jager J., Gremeaux T., Cormont M., et al. Interleukin-1β-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 148 1 (2007) 241-251
61. Arkan M.C., Hevener A.L., Greten F.R., et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11 (2005) 191-198
62. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
63. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
64. Gastaldelli A., Miyazaki Y., Mahankali A., et al. The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 29 10 (2006) 2275-2281
65. Jialal I., Stein D., Balis D., et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
66. Nesto R. C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin sensitizing treatment with thiazolidinediones. Diabet Med 21 (2004) 810-887
67. Ferrannini E. Is insulin resistance the cause of the metabolic syndrome?. Ann Med 38 (2006) 42-51
68. Carlson S.H., Shelton J., White C.R., et al. Elevated sympathetic nerve activity contributes to hypertension and salt sensitivity in diabetic obese zucker rats. Hypertension 35 (2000) 403-408
69. Kassab S., Kato T., Wilkins F.C., et al. Renal denervation attenuates the sodium retention and hypertention associated with obesity. Hypertension 25 (1995) 893-897
70. Aizawa-Abe M., Ogawa Y., Masuzaki H., et al. Pathophysiological role of leptin in obesity related hypertention. J Clin Invest 105 (2000) 1243-1252
71. Jones B.H., Standridge M.K., Taylor J.W., et al. Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am J Physiol 273 (1997) R236-R242
72. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular event in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342 (2000) 145-153
73. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 9311 (2002) 995-1003
74. Furuhashi M., Ura N., Higashiura K., et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42 (2003) 76-81
75. Bulow J., Madsen J., and Hojgaard L. Reversibility of the effects on local circulation of high lipid concentrations in blood. Scand J Clin Lab Invest 50 (1990) 291-296
76. Grekin R.J., Vollmer A.P., and Sider R.S. Pressor effects of portal venous oleate infusion: a proposed mechanism for obesity hypertension. Hypertension 26 (1995) 193-198
77. Stepniakowski K.T., Goodfriend T.L., and Egan B.M. Fatty acids enhance vascular α-adrenergic sensitivity. Hypertension 25 (1995) 774-778
78. Baron A.D., and Clark M.G. Role of blood flow in the regulation of muscle glucose uptake. Annu Rev Nutr 17 (1997) 487-499
79. Kim J.A., Montagnani M., Koh K.K., et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113 (2006) 1888-1904
80. Frank H.J., Levin E.R., Hu R.M., et al. Insulin stimulates endothelin binding and action on cultured vascular smooth muscle cells. Endocrinology 133 (1993) 1092-1097
81. Steinberg H.O., and Baron A.D. Vascular function, insulin resistance, and fatty acids. Diabetologia 45 5 (2002) 623-634
82. Eck S.L., Perkins S.L., Carr D.P., et al. Inhibition of phorbol ester-induced cellular adhesion by competitive binding of NF-kappaB in vivo. Mol Cell Biol 13 10 (1993) 6530-6536
83. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 11 (2000) 1296-1301
84. McLaughlin T., Abbasi F., Cheal K., et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139 (2003) 802-809
85. Bloomgarden Z.T. Measures of insulin sensitivity. Clin Lab Med 26 (2006) 611-633
86. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419